glp-1 drugs uses Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity GLP-1 weight loss drugs leave

Member Communication: Plans must prepare targeted outreach campaigns members potentially eligible for expanded GLP-1 coverage

Evernorth's pharmacy benefit services business generated $609 million in adjusted pretax earnings, reflecting the financial impact of previously announced client contract renewals and investments in the company's new rebate-free pharmacy benefit model, known as "Signature." The company is seeing strong early interest from health plans and employers as it prepares for a broader commercial rollout of Signature in 2028, Evanko said

From July 1, 2026, Medicare will cover Wegovy and Zepbound for weight loss through a temporary federal program called the Medicare GLP-1 bridge: with a new model coming into place in 2027

STANDARDS FOR EVALUATING THE EFFICACY OF OBESITY TREATMENT DRUGS The mechanisms of action and structural formulations of GLP-1RA-based therapies for obesity are detailed in Figs